- The current trial results of Veyonda, Noxopharm’s cancer treatment
- The role of big pharma and historical industry transactions
- The commercial pathway moving forward
Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company.
The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy.